Literature DB >> 23614534

Nuclear GSK-3β segregation in desmoid-type fibromatosis.

Cristiana Meneghello1, Bouchra Ousghir, Marco Rastrelli, Laura Anesi, Antonio Sommariva, Maria Cristina Montesco, Carlo Riccardo Rossi, Uros Hladnik, Daniela Segat.   

Abstract

AIMS: Desmoid-type fibromatosis (DF) is a rare benign myofibroblastic neoplasm of the connective tissue that is unable to metastasize but is associated with a high local recurrence rate. Nuclear β-catenin is the most commonly used histological marker of DF; however, clinical and biological predictive markers guiding the treatment and follow-up of DF are still lacking. Normally, β-catenin is regulated by the cytoplasmic multiprotein complex of adenomatous polyposis coli (APC), axin, casein kinase 1α (CK1α), and glycogen synthase kinase 3β (GSK-3β); this phosphorylates and degrades β-catenin, which would otherwise translocate to the nucleus. The aim of this study was to analyse the expression and localization of the β-catenin-protein complex of the Wnt pathway in cells isolated from DF patients. METHODS AND
RESULTS: We isolated cells from biopsies of DF patients, and demonstrated, by immunofluorescence and immunoblot analyses, that it is almost exclusively nuclear GSK-3β that colocalizes and interacts with β-catenin. The nuclear translocation of β-catenin and GSK-3β is not correlated with CTNNB1 mutations. In DF samples, the multiprotein complex is disrupted, as the cytoplasmic localization of APC and axin makes interaction with the nuclear β-catenin and GSK-3β impossible.
CONCLUSIONS: Our data suggest that GSK-3β is an additional DF marker with an important role in the aetiopathogenesis of this entity.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23614534     DOI: 10.1111/his.12133

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  4 in total

1.  Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).

Authors:  Shivaani Kummar; Geraldine O'Sullivan Coyne; Khanh T Do; Baris Turkbey; Paul S Meltzer; Eric Polley; Peter L Choyke; Robert Meehan; Rasa Vilimas; Yvonne Horneffer; Lamin Juwara; Ann Lih; Amul Choudhary; Sandra A Mitchell; Lee J Helman; James H Doroshow; Alice P Chen
Journal:  J Clin Oncol       Date:  2017-03-28       Impact factor: 44.544

2.  Characteristics of cultured desmoid cells with different CTNNB1 mutation status.

Authors:  Shunsuke Hamada; Hiroshi Urakawa; Eiji Kozawa; Eisuke Arai; Kunihiro Ikuta; Tomohisa Sakai; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Cancer Med       Date:  2015-12-21       Impact factor: 4.452

3.  Desmoid Fibromatosis of the Abdominal Wall: Surgical Resection and Reconstruction with Biological Matrix Egis®.

Authors:  Saveria Tropea; Simone Mocellin; Roberto Stramare; Maria Giuseppina Bonavina; Carlo Riccardo Rossi; Marco Rastrelli
Journal:  Case Rep Oncol       Date:  2017-02-17

4.  The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target.

Authors:  Maria Vittoria Enzo; Marco Rastrelli; Carlo Riccardo Rossi; Uros Hladnik; Daniela Segat
Journal:  Mol Cell Ther       Date:  2015-01-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.